ES2446215R2 - Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana. - Google Patents
Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana. Download PDFInfo
- Publication number
- ES2446215R2 ES2446215R2 ES201231274A ES201231274A ES2446215R2 ES 2446215 R2 ES2446215 R2 ES 2446215R2 ES 201231274 A ES201231274 A ES 201231274A ES 201231274 A ES201231274 A ES 201231274A ES 2446215 R2 ES2446215 R2 ES 2446215R2
- Authority
- ES
- Spain
- Prior art keywords
- human
- lymphoblastic leukemia
- therapeutic application
- against human
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención describe la aplicación terapéutica de agentes inhibidores de CD44 frente a la leucemia linfoblástica aguda (ALL) humana. En concreto, la presente invención hace referencia a un agente inhibidor de la función de CD44 para su uso en medicina, preferentemente para la prevención y/o tratamiento de la T-ALL humana, así como a una composición farmacéutica y un kit. La presente invención también hace referencia a un método de prevención y/o tratamiento de la T-ALL humana, a un modelo de células pre-leucémicas de la T-ALL humana en ratón inducidas por ICN1, y a un modelo de xenotrasplante en ratón para el estudio de las alteraciones moleculares tempranas que se asocian a la generación de las células que inician y mantienen la T-ALL humana.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201231274A ES2446215B1 (es) | 2012-08-06 | 2012-08-06 | Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana. |
| PCT/ES2013/070576 WO2014023869A2 (es) | 2012-08-06 | 2013-08-02 | Aplicacion terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201231274A ES2446215B1 (es) | 2012-08-06 | 2012-08-06 | Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ES2446215A2 ES2446215A2 (es) | 2014-03-06 |
| ES2446215R2 true ES2446215R2 (es) | 2014-04-23 |
| ES2446215B1 ES2446215B1 (es) | 2015-04-01 |
Family
ID=50068637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201231274A Withdrawn - After Issue ES2446215B1 (es) | 2012-08-06 | 2012-08-06 | Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana. |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2446215B1 (es) |
| WO (1) | WO2014023869A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023526529A (ja) | 2020-05-19 | 2023-06-21 | アンスティテュ・クリー | サイトカイン放出症候群の診断及び処置の方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004024750A2 (en) * | 2002-09-13 | 2004-03-25 | Dyax Corporation | Cd44-binding ligands |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2595657A4 (en) * | 2010-07-22 | 2015-09-23 | Univ California | ANTITUMOR ANTIBODY ANTIBODIES AND METHODS OF USING SAME |
-
2012
- 2012-08-06 ES ES201231274A patent/ES2446215B1/es not_active Withdrawn - After Issue
-
2013
- 2013-08-02 WO PCT/ES2013/070576 patent/WO2014023869A2/es active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| ES2446215A2 (es) | 2014-03-06 |
| ES2446215B1 (es) | 2015-04-01 |
| WO2014023869A2 (es) | 2014-02-13 |
| WO2014023869A3 (es) | 2014-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| GT201500312A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| GT201300243A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112016013109A2 (pt) | anticorpos de anti-siglec-8 e métodos de seu uso | |
| WO2015148415A3 (en) | Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease | |
| EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112018006039A2 (pt) | terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| CL2015002346A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2446215 Country of ref document: ES Kind code of ref document: B1 Effective date: 20150401 |
|
| FA2A | Application withdrawn |
Effective date: 20150804 |